Alar Pharmaceuticals’ long-acting ketamine shows early potential in TRD - Clinical Trials Arena2026-04-07 • Google News
ALAR: Q1 2026 revenue grew 64% YoY, with strong margins and a debt-free, cash-rich position - TradingView2 weeks ago • Google News